Skip to main content
Equibles
ITRMF logo

ITRMF · Iterum Therapeutics plc · Webcasts, Transcripts & Audio

Track ITRMF — free

Use ITRMF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ITRMF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.03 +0.01 (+34.78%) At close · Jul 21 Q3 2025 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Nov 14, 2025

Substantial doubt about the company's ability to continue as a going concern.

“This condition raises substantial doubt about the Company's ability to continue as a going concern for one year from the date these condensed consolidated financial statements are issued.”
View the 10-Q filed Nov 14, 2025
Market Cap
$446
Shares
44.66M
Volume · Jul 21 18.8K Avg daily vol (3M) 99.9K

Iterum Therapeutics plc Webcasts

Earnings calls, investor updates, investor days and conferences for Iterum Therapeutics plc (ITRMF), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY25 · Q3
2025-11-14
Iterum Therapeutics plc (ITRMF) Q3 2025 Earnings Call Transcript
Positive tone Orlynda Commercial Launch Sales Force / Field Operations Specialty Distribution Partners
Revenue
$390,000
Diluted EPS
$-0.20
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Iterum Therapeutics plc (ITRMF) Q2 2025 Earnings Call Transcript
Confident tone ORLYNVAH Commercial Launch Market Opportunity and Unmet Need Commercial Strategy and Sales Coverage
Diluted EPS
$-0.16
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Iterum Therapeutics plc (ITRMF) Q1 2025 Earnings Call Transcript
Positive tone ORLYNVAH launch and commercialization Competition Market opportunity and unmet need
Diluted EPS
$-0.14
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-07
Iterum Therapeutics plc (ITRMF) Q4 2024 Earnings Call Transcript
Positive tone FDA approval and ORLYNVAH launch readiness Cash runway and going concern Uncomplicated urinary tract infection market opportunity
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Iterum Therapeutics plc (ITRMF) Q3 2024 Earnings Call Transcript
Confident tone Cash runway and exchangeable notes Intellectual property and market exclusivity Strategic alternatives / partnership process
Diluted EPS
$-0.30
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Iterum Therapeutics plc (ITRMF) Q2 2024 Earnings Call Transcript
Positive tone FDA Advisory Committee and PDUFA Capital and Cash Runway Antibiotic Stewardship and Label
Diluted EPS
$-0.30
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Iterum Therapeutics plc (ITRMF) Q1 2024 Earnings Call Transcript
Confident tone FDA resubmission and review of oral sulopenem NDA Cash runway and financial position Market positioning and competition for uncomplicated UTIs
Diluted EPS
$-0.46
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-29
Iterum Therapeutics plc (ITRMF) Q4 2023 Earnings Call Transcript
Confident tone NDA resubmission and FDA review Financial position and cash runway Uncomplicated UTI market opportunity
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Iterum Therapeutics plc (ITRMF) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.30
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-11
Iterum Therapeutics plc (ITRMF) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.95
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-16
Iterum Therapeutics plc (ITRMF) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Iterum Therapeutics plc (ITRMF) Q3 2022 Earnings Call Transcript
Diluted EPS
$-2.38
▼ 950% YoY
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Iterum Therapeutics plc (ITRMF) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-12
Iterum Therapeutics plc (ITRMF) Q3 2021 Earnings Call Transcript
Diluted EPS
$0.28
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-13
Iterum Therapeutics plc (ITRMF) Q2 2021 Earnings Call Transcript
Diluted EPS
$0.60
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-14
Iterum Therapeutics plc (ITRMF) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-12
Iterum Therapeutics plc (ITRMF) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–17 of 17 webcasts
Key facts CIK 1659323 CUSIP G6333L200 Visit website Investor relations